The Primary Objective of This Study is to Determine Whether MICARDIS® Improves Insulin Sensitivity in Overweight or Obese, Non-diabetic, Normotensive Subjects

NCT00146289 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

138

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Insulin Resistance

Interventions

DRUG: MICARDIS® (telmisartan)

Sponsor

Boehringer Ingelheim